Biological Activity:

DMOG is a selective, competitive and cell permeable prolyl 4-hydroxylase (P4H) inhibitor. It inhibits hypoxia-inducible factor α (HIF-α) prolyl hydroxylase (HIF-PH). It acts to stabilize HIF-1α expression at normal oxygen tensions in cultured cells, at concentrations between 0.1 and 1 mM. DMOG acts as a pro-angiogenic compound, acting via the HIF-1α system.

How to Use:

In vitro: DMOG was used at 100 µM final concentration in vitro and in cellular assays.
In vivo: n/a

Reference:

• 1. Jaakkola P, et al. Targeting of HIF-alpha to the von Hippel-Lindau ubiquitylation complex by O2-regulated prolyl hydroxylation. (2001) Science. 292(5516):468-72. 
• 2. Lomb DJ, et al. Prolyl hydroxylase inhibitors depend on extracellular glucose and hypoxia-inducible factor (HIF)-2alpha to inhibit cell death caused by nerve growth factor (NGF) deprivation: evidence that HIF-2alpha has a role in NGF-promoted survival of sympathetic neurons. (2009) Mol Pharmacol. 75(5):1198-209. 
• 3. Ayrapetov MK, et al. Activation of Hif1α by the prolylhydroxylase inhibitor dimethyoxalyglycine decreases radiosensitivity. (2011) PLoS One. 6(10):e26064. 
• 4. Barnucz E, et al. Prolyl-hydroxylase inhibition preserves endothelial cell function in a rat model of vascular ischemia reperfusion injury. (2013) J Pharmacol Exp Ther. 345(1):25-31.

Products are for research use only. Not for human use.